Reciprocal regulation of platelet responses to P2Y and thromboxane receptor activation.
BACKGROUND
Thromboxane A(2) and ADP are two major platelet agonists that stimulate two sets of G protein-coupled receptors to activate platelets. Although aggregation responses to ADP and thromboxane desensitize, there are no reports currently addressing whether activation by one agonist may heterologously desensitize responses to the other.


OBJECTIVE
To demonstrate whether responses to ADP or U46619 may be modulated by prior treatment of platelets with the alternate agonist, revealing a level of cross-desensitization between receptor systems.


RESULTS
Here we show that pretreatment of platelets with either agonist substantially desensitizes aggregation responses to the other agonist. Calcium responses to thromboxane receptor activation are desensitized by preactivation of P2Y(1) but not P2Y(12) receptors. This heterologous desensitization is mediated by a protein kinase C (PKC)-independent mechanism. Reciprocally, calcium responses to ADP are desensitized by pretreatment of platelets with the thromboxane analogue, U46619, and P2Y(12)-mediated inhibition of adenylate cyclase is also desensitized by pretreatment with U46619. In this direction, desensitization is comprised of two components, a true heterologous component that is PKC-independent, and a homologous component that is mediated through stimulated release of dense granule ADP.


CONCLUSIONS
This study reveals cross-desensitization between ADP and thromboxane receptor signaling in human platelets. Cross-desensitization is mediated by protein kinases, involving PKC-dependent and independent pathways, and indicates that alterations in the activation state of one receptor may have effects upon the sensitivity of the other receptor system.
Barton
J F
JF
Department of Pharmacology, School of Medical Sciences, University Walk, Bristol, UK.
Hardy
A R
AR
Poole
A W
AW
Mundell
S J
SJ
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D000244:Adenosine Diphosphate / Q000737:chemistry; D001792:Blood Platelets / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D003600:Cytosol / Q000378:metabolism; D006801:Humans; D015539:Platelet Activation; D010974:Platelet Aggregation; D011493:Protein Kinase C / Q000378:metabolism; D018048:Receptors, Purinergic P2 / Q000737:chemistry*; D017482:Receptors, Thromboxane / Q000378:metabolism*; D012701:Serotonin / Q000737:chemistry; D015398:Signal Transduction; D013931:Thromboxanes / Q000737:chemistry
D018048:Receptors, Purinergic P2; D017482:Receptors, Thromboxane; D013931:Thromboxanes; D012701:Serotonin; D000244:Adenosine Diphosphate; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D000242:Cyclic AMP; D011493:Protein Kinase C; D002118:Calcium